Antibody-Drug Conjugates

Lonza strengthens ADC offering with Synaffix acquisition

01-Jun-2023 By Isabel Cameron

Lonza has acquired Synaffix B.V., a biotech company focused on commercializing its clinical-stage technology platform for the development of antibody drug conjugates (ADCs).

Synaffix and MacroGenics expand ADC partnership

14-Mar-2023 By Jane Byrne

The expanded antibody-drug conjugate (ADC) collaboration includes up to $2.2bn in total potential payments plus tiered royalties on net sales.

Sanofi increases China oncology focus with Innovent partnership

08-Aug-2022 By Rachel Arthur

Sanofi says a new collaboration with Innovent Biologics will help the company expand its oncology presence in China.

New year, new ADC deal: Abzena teams up with BiVictriX, Iksuda taps LegoChem again, Genmab secures access to Dutch tech

20-Jan-2022 By Jane Byrne

The past few weeks have witnessed a plethora of antibody-drug conjugate (ADC) related deals.

Former biopharmaceutical executives nabbed for insider trading

09-Dec-2021 By Jenni Spinner

The US Department of Justice has charged a former CFO and a former head of corporate communications for allegedly conducting an insider trading scheme.

Lonza to boost bioconjugation development and manufacturing capacity at Swiss site

22-Dec-2020 By Jane Byrne

Lonza has announced it is further expanding bioconjugation capabilities at its Visp site in Switzerland.

New antibody-drug conjugate partnership

16-Dec-2020 By Jane Byrne

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), has announced a new strategic partnership with ADC Biotechnology, a UK based company specializing in antibody-drug conjugates (ADCs).

Merck to acquire VelosBio, strengthening oncology pipeline with investigational antibody-drug conjugate

05-Nov-2020 By Rachel Arthur

Merck (MSD outside the US and Canada) will acquire San Diego’s VelosBio in a $2.75bn deal.

Immunomedics closes $459m stock offering to launch drug, scale manufacture

04-May-2020 By Ben Hargreaves

April saw the company add new CEO, receive approval for lead ADC drug, and launch a public offering of stock.

LakePharma and NJ Bio partner on ‘one-stop’ ADC manufacturing service

19-Feb-2020 By Vassia Barba

Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.

Immunomedics adopts PleaseReview to accelerate documentation management

11-Nov-2019 By Vassia Barba

Immunomedics to leverage Ideagen’s PleaseReview software service to support documentation management of its ADC development projects.

WuXi Biologics adds ADC commercial manufacturing at WuXi city facility

25-Jun-2019 By Maggie Lynch

WuXi Biologics expands its biologics conjugation solution center to include space for commercial manufacturing of antibody-drug conjugates for the biopharma industry.